Newark, DENCT06824064Now EnrollingIRB Ready

Metastatic Colorectal Cancer Clinical Trial in Newark, DE

Access cutting-edge metastatic colorectal cancer treatment through this clinical trial at a research site in Newark. Study-provided care at no cost to qualified participants.

Sponsored by Riboscience, LLC.

Quick Self-Assessment

See if you qualify for this Newark location

Preparing your pre-screening questions…

Expert Care in Newark

Access metastatic colorectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic colorectal cancer treatment provided free

Apply for This Newark Location

Check if you qualify for this metastatic colorectal cancer clinical trial in Newark, DE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newark

    Convenient for DE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newark site if eligible
  4. 4Begin participation

About This Metastatic Colorectal Cancer Study in Newark

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).

Sponsor: Riboscience, LLC.

Who Can Participate

Inclusion Criteria

At least 18 years of age on the day of signing informed consent.
Male and female subjects with advanced, metastatic, progressive CRC who have received, been ineligible for, intolerant to, or declined all approved standard of care (SOC) therapies for metastatic CRC, as per local SOC treatment regimens. Additionally, subjects must have documented PD based on two scans performed within 2 to 4 months of study initiation.
Have histologically or cytologically confirmed CRC diagnosis based on pathology report.
Willing to submit a pre-treatment tissue sample (archival, or fresh tissue if archival is not available).

Exclusion Criteria

Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy within 2 weeks prior to the first dose of study treatment; or if subject has not recovered (i.e., ≤ to Grade 1 or returned to baseline level) from AEs due to a previously administered agent; the following exceptions are allowed:
Palliative radiotherapy for bone metastases or soft tissue lesions should be completed \>7 days prior to the first dose of study treatment.
Hormone-replacement therapy or oral contraceptives.
Subjects with Grade 2 neuropathy or Grade 2 alopecia.
Subjects with evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
Malignancies other than indications open for enrollment within 3 years prior to Day 1, except for those with negligible risk of metastasis or death treated with expected curative outcome, undergoing active surveillance, or treatment-naïve for indolent tumors.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newark?

Yes, this clinical trial (NCT06824064) has an active research site in Newark, DE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Colorectal Cancer Treatment Options in Newark, DE

If you're searching for metastatic colorectal cancer treatment options in Newark, DE, this clinical trial (NCT06824064) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newark research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic colorectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Newark, DE

See all colorectal cancer clinical trials recruiting in Newark — not just this study.

Browse Colorectal Cancer Trials in Newark →

Browse More Trials by Condition

Colorectal Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Newark?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newark, DE